Jayesh Amin, Naga Sandhya Alle, Ami Patel, Bansi Prajapathi, Paresh Makwana, Jaya Prakash, Kota Murali Krishna
{"title":"FSHR和LHCGR基因多态性对采用全部冻结策略的促性腺激素释放激素拮抗剂方案临床结果的意义：病例对照研究。","authors":"Jayesh Amin, Naga Sandhya Alle, Ami Patel, Bansi Prajapathi, Paresh Makwana, Jaya Prakash, Kota Murali Krishna","doi":"10.18502/ijrm.v22i7.16962","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Follicle-stimulating hormone receptor (<i>FSHR</i>) and luteinizing hormone/choriogonadotropin receptor (<i>LHCGR</i>) are integral to ovarian function, facilitating follicle development and maturation through their respective hormonal interactions. The influence of receptor polymorphisms on the outcomes of freeze-all cycles remains unclear.</p><p><strong>Objective: </strong>This study investigates the impact of <i>FSHR</i> <i>N680S</i> and <i>LHCGR</i> <i>N312S</i> polymorphisms on clinical outcomes in freeze-all cycles.</p><p><strong>Materials and methods: </strong>Women undergoing controlled ovarian stimulation for assisted reproductive technology participated in this study. They were administered a gonadotropin-releasing hormone antagonist protocol, with recombinant follicle-stimulating hormone (rFSH) dosages adjusted according to age, body mass index, antral follicle count, and individual hormonal responses. Additionally, human menopausal gonadotropin dosages were tailored based on the <i>LHCGR</i> <i>N312S</i> genetic variant.</p><p><strong>Results: </strong>Analysis revealed no significant differences in age, body mass index, antral follicle count, or marital status across the genotypes of <i>FSHR</i> <i>N680S</i> and <i>LHCGR</i> <i>N312S</i>. However, notable differences were observed in the rFSH dosage required daily and in total among the FSHR polymorphism genotypes. Genotypes of the <i>LHCGR</i> polymorphism correlated with fewer stimulation days. A significant interaction was observed between the 2 polymorphisms concerning total rFSH dosage.</p><p><strong>Conclusion: </strong>The presence of serine in the <i>FSHR</i> polymorphism was associated with higher rFSH dosage requirements. Both <i>FSHR</i> <i>N680S</i> and <i>LHCGR</i> <i>N312S</i> polymorphisms significantly influenced clinical pregnancy and live birth outcomes in freeze-all cycles, underscoring the potential of a pharmacogenomic approach to optimize hormone supplementation in controlled ovarian stimulation protocols during assisted reproductive technology treatments.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"22 7","pages":"539-552"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441282/pdf/","citationCount":"0","resultStr":"{\"title\":\"Significance of <i>FSHR</i> and <i>LHCGR</i> gene polymorphisms on clinical outcomes in gonadotropin-releasing hormone antagonist protocol with freeze-all strategy: A case-control study.\",\"authors\":\"Jayesh Amin, Naga Sandhya Alle, Ami Patel, Bansi Prajapathi, Paresh Makwana, Jaya Prakash, Kota Murali Krishna\",\"doi\":\"10.18502/ijrm.v22i7.16962\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Follicle-stimulating hormone receptor (<i>FSHR</i>) and luteinizing hormone/choriogonadotropin receptor (<i>LHCGR</i>) are integral to ovarian function, facilitating follicle development and maturation through their respective hormonal interactions. The influence of receptor polymorphisms on the outcomes of freeze-all cycles remains unclear.</p><p><strong>Objective: </strong>This study investigates the impact of <i>FSHR</i> <i>N680S</i> and <i>LHCGR</i> <i>N312S</i> polymorphisms on clinical outcomes in freeze-all cycles.</p><p><strong>Materials and methods: </strong>Women undergoing controlled ovarian stimulation for assisted reproductive technology participated in this study. They were administered a gonadotropin-releasing hormone antagonist protocol, with recombinant follicle-stimulating hormone (rFSH) dosages adjusted according to age, body mass index, antral follicle count, and individual hormonal responses. Additionally, human menopausal gonadotropin dosages were tailored based on the <i>LHCGR</i> <i>N312S</i> genetic variant.</p><p><strong>Results: </strong>Analysis revealed no significant differences in age, body mass index, antral follicle count, or marital status across the genotypes of <i>FSHR</i> <i>N680S</i> and <i>LHCGR</i> <i>N312S</i>. However, notable differences were observed in the rFSH dosage required daily and in total among the FSHR polymorphism genotypes. Genotypes of the <i>LHCGR</i> polymorphism correlated with fewer stimulation days. A significant interaction was observed between the 2 polymorphisms concerning total rFSH dosage.</p><p><strong>Conclusion: </strong>The presence of serine in the <i>FSHR</i> polymorphism was associated with higher rFSH dosage requirements. Both <i>FSHR</i> <i>N680S</i> and <i>LHCGR</i> <i>N312S</i> polymorphisms significantly influenced clinical pregnancy and live birth outcomes in freeze-all cycles, underscoring the potential of a pharmacogenomic approach to optimize hormone supplementation in controlled ovarian stimulation protocols during assisted reproductive technology treatments.</p>\",\"PeriodicalId\":14386,\"journal\":{\"name\":\"International Journal of Reproductive Biomedicine\",\"volume\":\"22 7\",\"pages\":\"539-552\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441282/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Reproductive Biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/ijrm.v22i7.16962\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Reproductive Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijrm.v22i7.16962","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Significance of FSHR and LHCGR gene polymorphisms on clinical outcomes in gonadotropin-releasing hormone antagonist protocol with freeze-all strategy: A case-control study.
Background: Follicle-stimulating hormone receptor (FSHR) and luteinizing hormone/choriogonadotropin receptor (LHCGR) are integral to ovarian function, facilitating follicle development and maturation through their respective hormonal interactions. The influence of receptor polymorphisms on the outcomes of freeze-all cycles remains unclear.
Objective: This study investigates the impact of FSHRN680S and LHCGRN312S polymorphisms on clinical outcomes in freeze-all cycles.
Materials and methods: Women undergoing controlled ovarian stimulation for assisted reproductive technology participated in this study. They were administered a gonadotropin-releasing hormone antagonist protocol, with recombinant follicle-stimulating hormone (rFSH) dosages adjusted according to age, body mass index, antral follicle count, and individual hormonal responses. Additionally, human menopausal gonadotropin dosages were tailored based on the LHCGRN312S genetic variant.
Results: Analysis revealed no significant differences in age, body mass index, antral follicle count, or marital status across the genotypes of FSHRN680S and LHCGRN312S. However, notable differences were observed in the rFSH dosage required daily and in total among the FSHR polymorphism genotypes. Genotypes of the LHCGR polymorphism correlated with fewer stimulation days. A significant interaction was observed between the 2 polymorphisms concerning total rFSH dosage.
Conclusion: The presence of serine in the FSHR polymorphism was associated with higher rFSH dosage requirements. Both FSHRN680S and LHCGRN312S polymorphisms significantly influenced clinical pregnancy and live birth outcomes in freeze-all cycles, underscoring the potential of a pharmacogenomic approach to optimize hormone supplementation in controlled ovarian stimulation protocols during assisted reproductive technology treatments.
期刊介绍：
The International Journal of Reproductive BioMedicine (IJRM), formerly published as "Iranian Journal of Reproductive Medicine (ISSN: 1680-6433)", is an international monthly scientific journal for who treat and investigate problems of infertility and human reproductive disorders. This journal accepts Original Papers, Review Articles, Short Communications, Case Reports, Photo Clinics, and Letters to the Editor in the fields of fertility and infertility, ethical and social issues of assisted reproductive technologies, cellular and molecular biology of reproduction including the development of gametes and early embryos, assisted reproductive technologies in model system and in a clinical environment, reproductive endocrinology, andrology, epidemiology, pathology, genetics, oncology, surgery, psychology, and physiology. Emerging topics including cloning and stem cells are encouraged.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
